A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Public ClinicalTrials.gov record NCT03215706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
Study identification
- NCT ID
- NCT03215706
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 719 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Biological
- Nivolumab Biological
- Carboplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
- Cisplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2017
- Primary completion
- Aug 15, 2019
- Completion
- Oct 17, 2024
- Last update posted
- Dec 16, 2025
2017 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Health Systems | Colorado Springs | Colorado | 80909 | — |
| Local Institution - 0044 | Plainville | Connecticut | 06062 | — |
| Local Institution - 0045 | Jacksonville | Florida | 32207 | — |
| Local Institution - 0029 | Marietta | Georgia | 30060 | — |
| Local Institution - 0091 | Wichita | Kansas | 67214 | — |
| Local Institution - 0004 | Lexington | Kentucky | 40503 | — |
| Local Institution - 0105 | Detroit | Michigan | 48202 | — |
| Local Institution - 0058 | Johnson City | New York | 13790 | — |
| Local Institution - 0098 | Mineola | New York | 11501 | — |
| Local Institution - 0095 | Columbus | Ohio | 43210 | — |
| Local Institution - 0006 | Lancaster | Pennsylvania | 17602 | — |
| Local Institution - 0047 | Pittsburgh | Pennsylvania | 15213 | — |
| Local Institution - 0093 | Pittsburgh | Pennsylvania | 15224 | — |
| Local Institution - 0094 | Charleston | South Carolina | 29414 | — |
| Southwest Regional Cancer Clinic | St. George | Utah | 84770 | — |
| Local Institution - 0099 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03215706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03215706 live on ClinicalTrials.gov.